ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Curis Lifesciences filed its Reg 32 statement of IPO fund utilisation for the half-year to September 30, 2026. The filing reports no deviation or variation, with ₹2,295.11 lakhs utilised against ₹2,752 lakhs proposed.
Curis Lifesciences Ltd reported revenue from operations of ₹34.1 Cr (+22.2% YoY) and net profit of ₹4.1 Cr (-2.4% YoY) for H1 FY27.
Curis Lifesciences Limited informed that it is not required to submit a Corporate Governance Report, as its securities are listed on the SME platform.
Curis Lifesciences Limited conducted its 10th Annual General Meeting on September 29, 2026, to transact various agenda items, including financial statement adoption and director appointments.
Curis Lifesciences filed its 10th AGM notice and FY 2025-26 Annual Report. The meeting is scheduled for September 29, 2026.
Curis Lifesciences Limited approved the Director's Report, related party transactions, and scheduled its 10th Annual General Meeting for September 29, 2026. Board outcomes were finalized.
Curis Lifesciences Limited announced the resignation of Mr. Nikhil Purohit as Company Secretary and Compliance Officer, effective September 3, 2026.
Curis Lifesciences Limited submitted the RTA confirmation certificate for the quarter ended June 30, 2026, as required under SEBI Regulation 74(5).
Curis Lifesciences Limited has acquired a 49.95% stake in CUROSUN PHARMACEUTICAL NIG LTD, Nigeria, for Rs. 5 Lakhs to expand its pharmaceutical market presence.
Curis Lifesciences paid a Rs. 5,900 fine to NSE for delayed RPT disclosure compliance. The Board attributed the delay to technical portal errors.
Curis Lifesciences appointed Mr. Devabhai Hamirbhai Jadeja as an Independent Director for five years. He brings extensive experience in financial management and accounting to the board.
Curis Lifesciences Limited submitted clarifications and corrected financial results for FY2026 following NSE queries. The update rectifies XBRL discrepancies and integrates issue proceed utilization disclosures.
Curis Lifesciences announced the resignation of Independent Director Mr. Chand Rameshbhai Kanabar effective July 3, 2026. His departure is due to pre-occupancy and professional commitments.
Curis Lifesciences received a fine of ₹0.0059 Crore from NSE. This penalty was imposed for delayed compliance with SEBI Listing Regulations.
Curis Lifesciences reported its IPO fund utilization for FY2025-26, confirming ₹27.52 Crore was raised. The company reported no deviations in the deployment of these proceeds.
Curis Lifesciences Ltd reported revenue from operations of ₹32.7 Cr (-4.9% YoY) and net profit of ₹2.7 Cr (-32.5% YoY) for H2 FY26.
Curis Lifesciences Limited approved its audited standalone financial results for the year ended March 31, 2026. The results provide essential year-end performance data for investors.
Curis Lifesciences Limited filed its annual SDD compliance certificate for FY2026. The company confirmed full adherence to SEBI Insider Trading regulations regarding digital databases.
Curis Lifesciences Limited scheduled a board meeting on May 30, 2026, to approve audited annual results. The company's trading window remains closed for designated persons.